Breast Cancer | Specialty

European Commission Recommends Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer

December 19th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval for the use of trastuzumab deruxtecan monotherapy for adults with unresectable or metastatic HER2-low breast cancer.

Sacituzumab Govitecan, Trastuzumab Deruxtecan Highlight Expanding Role of ADCs in TNBC

December 17th 2022

Nour Abuhadra, MD, discusses what the data from DESTINY-Breast04 means for trastuzumab deruxtecan in the triple-negative breast cancer space and future areas of research for antibody-drug conjugates in this disease.

FDA Approves Updated Labeling for Capecitabine Tablets

December 15th 2022

The FDA has approved updated labeling for capecitabine tablets (Xeloda) under an initiative aimed to ensure labeling information is clinically meaningful and scientifically up to date.

Dr. Pakkala on Integrating Local Therapy into HER2+ Breast Cancer Treatment

December 15th 2022

Suchita Pakkala, MD, discusses ongoing efforts to integrate local therapy into HER2-positive breast cancer treatment.

Updated EMERALD Data Support Oral SERD Elacestrant As a Potential Option for Metastatic Hormone Receptor–Positive Breast Cancer

December 14th 2022

The oral selective estrogen receptor degrader elacestrant has shown promise over standard second-line treatment, such as fulvestrant, for patients with metastatic hormone receptor–positive breast cancer.

Focus on Pathways: SERMS in Metastatic Breast Cancer

December 12th 2022

Neoadjuvant Platinum Plus Standard Chemotherapy Improves Survival in TNBC

December 10th 2022

The addition of carboplatin to taxane-anthracycline chemotherapy led to a significant improvement in event-free survival and overall survival as neoadjuvant therapy in patients with operable and locally advanced triple-negative breast cancer.

Sacituzumab Govitecan Shows Sustained Survival Improvement in HR+/HER2– Breast Cancer

December 10th 2022

Sacituzumab govitecan prolonged survival vs treatment of physician’s choice in pretreated patients with hormone receptor–positive, HER2-negative metastatic breast cancer regardless of Trop-2 expression, according to updated findings from the phase 3 TROPiCS-02 trial.

Neoadjuvant Olaparib Combo Fails to Surpass Carboplatin/Paclitaxel in HER2– Early Breast Cancer

December 9th 2022

Long-term clinical data failed to show a benefit of neoadjuvant olaparib (Lynparza) plus paclitaxel vs carboplatin plus paclitaxel in patients with HER2-negative early breast cancer with homologous recombination deficiency.

Neoadjuvant Cemiplimab/REGN3767 Plus Paclitaxel Improves pCR in Early-stage, High-risk HER2– Breast Cancer

December 9th 2022

The addition of cemiplimab and REGN3767 to paclitaxel improved pathologic complete response vs paclitaxel alone in patients with triple-negative and hormone receptor–positive, HER2-negative breast cancer, according to data from the phase 2 I-SPY2 trial.

Trastuzumab Deruxtecan With or Without Pertuzumab Demonstrates Early Safety and Efficacy Signals in HER2+ MBC

December 9th 2022

Trastuzumab deruxtecan, both as monotherapy and in combination with pertuzumab, displayed encouraging efficacy with no new safety signals among patients with HER2-positive metastatic breast cancer, according to findings from the dose expansion part of the phase 1b/2 DESTINY-Breast07 trial.

Dr. Jacot on Ribociclib Dose Reduction in HR+/HER2– Advanced Breast Cancer

December 9th 2022

William Jacot, MD, PhD, discusses updated efficacy and safety results from the phase 2 AMALEE trial.

CTC Count-driven Approach to First-line Treatment in Metastatic Breast Cancer Improves Survival

December 9th 2022

Using circulating tumor cell count as a guide to first-line treatment, either with chemotherapy or endocrine therapy, resulted in an improvement in overall survival compared with physician’s choice of treatment without CTC count for patients with metastatic, hormone receptor–positive/HER2-negative breast cancer.

Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast Cancer

December 8th 2022

Treatment with the oral selective estrogen receptor degrader elacestrant following treatment with CDK4/6 inhibitors improved progression-free survival outcomes vs standard care options in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Dr. Hurvitz on Sequencing Therapeutic Options in HER2+ Breast Cancer

December 8th 2022

Sara A. Hurvitz, MD, discusses sequencing therapeutic options for patients with HER2-positive breast cancer. 

Palbociclib Plus Fulvestrant Fails to Improve PFS in ER+/HER2- Breast Cancer After Progression on a CDK4/6 inhibitor

December 8th 2022

Palbociclib plus fulvestrant did not elicit a progression-free survival benefit vs fulvestrant alone in patients with estrogen receptor–positive/HER2-negative breast cancer who had progressed on prior treatment with a CDK4/6 inhibitor and aromatase inhibitor.

ARV-471 Monotherapy Demonstrates Clinical Benefit in ER+/HER2- Advanced Breast Cancer

December 8th 2022

ARV-471 monotherapy elicited a significant clinical benefit rate in patients with estrogen receptor–positive/HER2-negative locally advanced or metastatic breast cancer who had undergone prior hormonal therapy and chemotherapy, including those with ESR1 mutations.

Dr. Bardia on Elacestrant in ER+/HER2– Metastatic Breast Cancer

December 8th 2022

Aditya Bardia, MD, MPH, discusses the use of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

Real-world Data Confirm Safety Profile for Tucatinib Plus Trastuzumab/Capecitabine in HER2+ Breast Cancer

December 8th 2022

The safety profile for the combination of tucatinib, trastuzumab, and capecitabine from the phase 3 HER2CLIMB trial was confirmed with real-world data for patients with HER2-positive metastatic breast cancer.

Eribulin Demonstrates Comparable Efficacy to Traditional Chemotherapy Options in HER2-low and HER2-0 Metastatic Breast Cancer

December 7th 2022

Eribulin mesylate demonstrated a trend toward improved outcomes vs other chemotherapy options of physician’s choice in patients with HER2-low or HER2-0 metastatic breast cancer who were previously treated with at least 1 chemotherapy.